PMID- 37150516
OWN - NLM
STAT- MEDLINE
DCOM- 20230509
LR  - 20230530
IS  - 2093-5978 (Electronic)
IS  - 2093-596X (Print)
IS  - 2093-596X (Linking)
VI  - 38
IP  - 2
DP  - 2023 Apr
TI  - New Insights into Calorie Restriction Induced Bone Loss.
PG  - 203-213
LID - 10.3803/EnM.2023.1673 [doi]
AB  - Caloric restriction (CR) is now a popular lifestyle choice due to its ability in 
      experimental animals to improve lifespan, reduce body weight, and lessen 
      oxidative stress. However, more and more emerging evidence suggests this 
      treatment requires careful consideration because of its detrimental effects on 
      the skeletal system. Experimental and clinical studies show that CR can suppress 
      bone growth and raise the risk of fracture, but the specific mechanisms are 
      poorly understood. Reduced mechanical loading has long been thought to be the 
      primary cause of weight loss-induced bone loss from calorie restriction. Despite 
      fat loss in peripheral depots with calorie restriction, bone marrow adipose 
      tissue (BMAT) increases, and this may play a significant role in this 
      pathological process. Here, we update recent advances in our understanding of the 
      effects of CR on the skeleton, the possible pathogenic role of BMAT in CR-induced 
      bone loss, and some strategies to mitigate any potential side effects on the 
      skeletal system.
FAU - Liu, Linyi
AU  - Liu L
AD  - MaineHealth Institute for Research, Scarborough, ME, USA.
FAU - Rosen, Clifford J
AU  - Rosen CJ
AD  - MaineHealth Institute for Research, Scarborough, ME, USA.
LA  - eng
PT  - Journal Article
DEP - 20230427
PL  - Korea (South)
TA  - Endocrinol Metab (Seoul)
JT  - Endocrinology and metabolism (Seoul, Korea)
JID - 101554139
SB  - IM
MH  - Animals
MH  - *Caloric Restriction/adverse effects
MH  - *Adipose Tissue
PMC - PMC10164494
OTO - NOTNLM
OT  - Bone and bones
OT  - Bone marrow adipose tissue
OT  - Caloric restriction
OT  - Exercise
OT  - Parathyroid hormone
OT  - Vitamin D
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2023/05/08 00:41
MHDA- 2023/05/09 06:42
PMCR- 2023/04/01
CRDT- 2023/05/07 19:51
PHST- 2023/02/02 00:00 [received]
PHST- 2023/03/30 00:00 [accepted]
PHST- 2023/05/09 06:42 [medline]
PHST- 2023/05/08 00:41 [pubmed]
PHST- 2023/05/07 19:51 [entrez]
PHST- 2023/04/01 00:00 [pmc-release]
AID - EnM.2023.1673 [pii]
AID - enm-2023-1673 [pii]
AID - 10.3803/EnM.2023.1673 [doi]
PST - ppublish
SO  - Endocrinol Metab (Seoul). 2023 Apr;38(2):203-213. doi: 10.3803/EnM.2023.1673. 
      Epub 2023 Apr 27.